Download Publications for Niall Tebbutt Publications for Niall Tebbutt 2016

Publications for Niall Tebbutt
Publications for Niall Tebbutt
2016
Franko, J., Shi, Q., Meyers, J., Maughan, T.,
Adams, R., Seymour, M., Saltz, L., Punt, C.,
Koopman, M., Tebbutt, N., et al (2016).
Prognosis of patients with peritoneal metastatic
colorectal cancer given systemic therapy: an
analysis of individual patient data from
prospective randomised trials from the Analysis
and Research in Cancers of the Digestive System
(ARCAD) database. The Lancet Oncology,
17(12), 1709-1719. <a
href="http://dx.doi.org/10.1016/S1470-2045(16)
30500-9">[More Information]</a>
2014
Bruhn, M., Townsend, A., Lee, C., Shivasami,
A., Price, T., Wrin, J., Arentz, G., Tebbutt, N.,
Hocking, C., Cunningham, D., et al (2014).
Proangiogenic tumor proteins as potential
predictive or prognostic biomarkers for
bevacizumab therapy in metastatic colorectal
cancer. International Journal of Cancer, 135(3),
731-741. <a
href="http://dx.doi.org/10.1002/ijc.28698">[Mor
e Information]</a>
Carter, H., Zannino, D., Simes, R., Schofield, D.,
Howard, K., Zalcberg, J., Price, T., Tebbutt, N.
(2014). The cost effectiveness of bevacizumab
when added to capecitabine, with or without
mitomycin-C, in first line treatment of metastatic
colorectal cancer: Results from the Australasian
phase III MAX study. European Journal of
Cancer, 50(3), 535-543. <a
href="http://dx.doi.org/10.1016/j.ejca.2013.09.02
8">[More Information]</a>
Segelov, E., Chan, D., Shapiro, J., Price, T.,
Karapetis, C., Tebbutt, N., Pavlakis, N. (2014).
The role of biological therapy in metastatic
colorectal cancer after first-line treatment: a
meta-analysis of randomised trials. British
Journal of Cancer, 111(6), 1122-1131. <a
href="http://dx.doi.org/10.1038/bjc.2014.404">[
More Information]</a>
2013
Vickers, M., Karapetis, C., Tu, D., O'Callaghan,
C., Price, T., Tebbutt, N., van Hazel, G., Shapiro,
J., Pavlakis, N., Gibbs, P., Simes, R., et al
(2013). Association of hypomagnesemia with
inferior survival in a phase III, randomized study
of cetuximab plus best supportive care versus
best supportive care alone: NCIC CTG/AGITG
CO.17. Annals of Oncology, 24(4), 953-960. <a
href="http://dx.doi.org/10.1093/annonc/mds577"
>[More Information]</a>
Price, T., Segelov, E., Burge, M., Haller, D.,
Ackland, S., Tebbutt, N., Karapetis, C., Pavlakis,
N., Sobrero, A., Cunningham, D., et al (2013).
Current opinion on optimal treatment for
colorectal cancer. Expert Review of Anticancer
Therapy, 13(5), 597-611. <a
href="http://dx.doi.org/10.1586/era.13.37">[Mor
e Information]</a>
Tebbutt, N., Parry, M., Zannino, D., Strickland,
A., van Hazel, G., Pavlakis, N., Ganju, V.,
Mellor, D., Dobrovic, A., Gebski, V. (2013).
Docetaxel plus cetuximab as second-line
treatment for docetaxel-refractory
oesophagogastric cancer: the AGITG ATTAX2
trial. British Journal of Cancer, 108(4), 771-774.
<a
href="http://dx.doi.org/10.1038/bjc.2013.41">[M
ore Information]</a>
Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N.,
Desai, J., Michael, M., Tebbutt, N., Price, T.,
Tabernero, J. (2013). Overview of biomarkers in
metastatic colorectal cancer: Tumour, blood and
patient-related factors. Critical Reviews in
Oncology / Hematology (online), 85(2), 121-135.
<a
href="http://dx.doi.org/10.1016/j.critrevonc.2012
.06.001">[More Information]</a>
2012
Price, T., Zannino, D., Wilson, C., Simes, R.,
Cassidy, J., Van Hazel, G., Robinson, B., Broad,
A., Ganju, V., Ackland, S., Tebbutt, N. (2012).
Bevacizumab is equally effective and no more
toxic in elderly patients with advanced colorectal
cancer: a subgroup analysis from the AGITG
MAX trial: an international randomised
controlled trial of Capecitabine, Bevacizumab
and Mitomycin C. Annals of Oncology, 23(6),
1531-1536. <a
href="http://dx.doi.org/10.1093/annonc/mdr488"
>[More Information]</a>
Neoptolemos, J., Moore, M., Cox, T., Valle, J.,
Palmer, D., McDonald, A., Carter, R., Tebbutt,
N., Dervenis, C., Smith, D., et al (2012). Effect
of adjuvant chemotherapy with fluorouracil plus
folinic acid or gemcitabine vs observation on
survival in patients with resected periampullary
adenocarcinoma: the ESPAC-3 periampullary
cancer randomized trial. JAMA, 308(2), 147-156.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=22782416">[More Information]</a>
Price, T., Shapiro, J., Segelov, E., Karapetis, C.,
Pavlakis, N., Van Cutsem, E., Shah, M., Kang,
Y., Tebbutt, N. (2012). Management of advanced
gastric cancer. Expert Review of
Gastroenterology and Hepatology, 6(2),
199-209. <a
href="http://dx.doi.org/10.1586/egh.11.103">[M
ore Information]</a>
Publications for Niall Tebbutt
2011
Deb, S., Ferraro, D., Tebbutt, N., Fox, S. (2011).
Australian perspective on the role of targeted
therapies in gastroesophageal cancer. Cancer
Forum, 35(3), 150-156.
Price, T., Hardingham, J., Lee, C., Townsend,
A., Wrin, J., Chua, A., Shivasami, A., Parry, M.,
Weikhardt, A., Tebbutt, N., et al (2011). Impact
of KRAS and BRAF Gene Mutation Status on
Outcomes From the Phase III AGITG MAX
Trial of Capecitabine Alone or in Combination
With Bevacizumab and Mitomycin in Advanced
Colorectal Cancer. Journal of Clinical Oncology,
29(19), 2675-2682. <a
href="http://dx.doi.org/10.1200/JCO.2010.34.55
20">[More Information]</a>
Tebbutt, N., Murphy, F., Zannino, D., Wilson,
C., Parry, M., Abdi, E., Strickland, A.,
Lowenthal, R., Marx, G., Karapetis, C., Shannon,
J., Simes, R., et al (2011). Risk of arterial
thromboembolic events in patients with
advanced colorectal cancer receiving
bevacizumab. Annals of Oncology, 22(8),
1834-1838. <a
href="http://dx.doi.org/10.1093/annonc/mdq702"
>[More Information]</a>
Clarke, S., Yip, S., Brown, C., van Hazel, G.,
Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt,
N., Buck, M., Lowenthal, R., Boland, A.,
Gebski, V., Simes, R., et al (2011). Single-agent
irinotecan or 5-fluorouracil and leucovorin
(FOLFIRI) as second-line chemotherapy for
advanced colorectal cancer; results of a
randomised phase II study (DaVINCI) and
meta-analysis. European Journal of Cancer,
47(12), 1826-1836. <a
href="http://dx.doi.org/10.1016/j.ejca.2011.04.02
4">[More Information]</a>
2010
Tebbutt, N., Wilson, K., Gebski, V., Cummins,
M., Zannino, D., van Hazel, G., Robinson, B.,
Broad, A., Ganju, V., Ackland, S., Stockler, M.,
Simes, R., et al (2010). Capecitabine,
Bevacizumab and Mitomycin in First-Line
Treatment of Metastatic Colorectal Cancer:
Results of the Australasian Gastrointestinal
Trials Group Randomized, Phase III MAX
Study. Journal of Clinical Oncology, 28(19),
3191-3198. <a
href="http://dx.doi.org/10.1200/JCO.2009.27.77
23">[More Information]</a>
Tebbutt, N., Karapetis, C., Segelov, E., Pavlakis,
N., Cunningham, D., Sobrero, A., Haller, D.,
Shapiro, J. (2010). Current Opinion on Optimal
Treatment Choices in First-line Therapy for
Advanced or Metastatic Colorectal Cancer:
Report From the Adelaide Colorectal Tumour
Group Meeting; Stockholm, Sweden; September
2008. Clinical Colorectal Cancer, 9(1), 8-14. <a
href="http://dx.doi.org/10.3816/CCC.2010.n.001
">[More Information]</a>
Goldstein, D., Gainford, M., Brown, C., Tebbutt,
N., Ackland, S., van Hazel, G., Jefford, M.,
Abdi, E., Selva-Nayagam, S., Gebski, V., Miller,
D., et al (2010). Fixed-dose-rate gemcitabine
combined with cisplatin in patients with
inoperable biliary tract carcinomas. Cancer
Chemotherapy and Pharmacology, , 1-7. <a
href="http://dx.doi.org/10.1007/s00280-010-135
1-8">[More Information]</a>
Tebbutt, N., Parry, M., Sourjina, T., Strickland,
A., van Hazel, G., Ganju, V., Gibbs, D., Stockler,
M., Gebski, V., Zalcberg, J. (2010). Randomised,
non-comparative phase II study of weekly
docetaxel with cisplatin and 5-fluorouracil or
with capecitabine in oesophagogastric cancer:
the AGITG ATTAX trial. British Journal of
Cancer, 102(3), 475-481. <a
href="http://dx.doi.org/10.1038/sj.bjc.6605522">
[More Information]</a>
2009
Hicks, S., James, R., Wong, N., Tebbutt, N.,
Wilson, C., Australasian Gastro-Intestinal Trials
Group, -. (2009). A case study evaluation of
ethics review systems for multicentre clinical
trials. Medical Journal of Australia, 191(5),
280-282. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=19740053">[More Information]</a>
Mittman, N., Au, H., Tu, D., O'Callaghan, C.,
Isogai, P., Karapetis, C., Zalcberg, J., Evans, W.,
Moore, M., Siddiqui, J., Simes, R., Tebbutt, N.,
et al (2009). Prospective Cost-Effectiveness
Analysis of Cetuximab in Metastatic Colorectal
Cancer: Evaluation of National Cancer Institute
of Canada Clinical Trials Group CO.17 Trial.
Journal of the National Cancer Institute,
101(17), 1182-1192. <a
href="http://dx.doi.org/10.1093/jnci/djp232">[M
ore Information]</a>
2008
Karapetis, C., Khambata-Ford, S., Jonker, D.,
O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R.,
Chalchal, H., Shapiro, J., Robitaille, S., et al
(2008). K-ras Mutations and Benefit from
Cetuximab in Advanced Colorectal Cancer. New
England Journal of Medicine, 359(17),
1757-1765. <a
href="http://dx.doi.org/10.1056/NEJMoa080438
5">[More Information]</a>
2007
Scott, A., Tebbutt, N., Lee, F., Cavicchiolo, T.,
Liu, Z., Gill, S., Poon, A., Hopkins, W., Smyth,
Publications for Niall Tebbutt
F., Davis, I., et al (2007). A phase I
biodistribution and pharmacokinetic trial of
humanized monoclonal antibody Hu3s193 in
patients with advanced epithelial cancers that
express the Lewis-Y antigen. Clinical Cancer
Research, 13(11), 3286-3292. <a
href="http://dx.doi.org/10.1158/1078-0432.CCR07-0284">[More Information]</a>
Jonker, D., O’Callaghan, C., Karapetis, C.,
Zalcberg, J., Tu, D., Au, H., Berry, S., Krahn,
M., Price, T., Simes, R., et al (2007). Cetuximab
for the Treatment of Colorectal Cancer. New
England Journal of Medicine, 357(20),
2040-2048. <a
href="http://dx.doi.org/10.1056/NEJMoa071834
">[More Information]</a>
2005
Chong, G., Lee, F., Hopkins, W., Tebbutt, N.,
Cebon, J., Mountain, A., Chappell, B.,
Papenfuss, A., Schleyer, P., Davis, I., et al
(2005). Phase I trial of 131I-huA33 in patients
with advanced colorectal carcinoma. Clinical
Cancer Research, 11(13), 4818-4826. <a
href="http://dx.doi.org/10.1158/1078-0432.CCR04-2330">[More Information]</a>